Lv3
230 积分 2023-09-15 加入
NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023
23天前
已完结
Non–Small Cell Lung Cancer, Version 4.2024
23天前
已完结
Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial
23天前
已完结
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
29天前
已完结
Prognostic factors for overall survival of stage III non-small cell lung cancer patients on computed tomography: A systematic review and meta-analysis
1个月前
已完结
Cancer statistics, 2024
1个月前
已完结
Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer
1个月前
已完结
Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non–small cell lung cancer: A network meta‐analysis of randomized trials
1个月前
已完结
Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non‐small cell lung cancer
1个月前
已完结
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis
1个月前
已完结
皖公网安备34019202002308
